Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial
Open Access
- 1 May 2018
- journal article
- research article
- Published by Elsevier BV in Molecular Genetics and Metabolism
- Vol. 124 (1), 20-26
- https://doi.org/10.1016/j.ymgme.2018.03.003
Abstract
No abstract availableKeywords
Funding Information
- BioMarin Pharmaceutical Inc.
This publication has 23 references indexed in Scilit:
- Cognitive profile and mental health in adult phenylketonuria: A PKU-COBESO study.Neuropsychology, 2017
- Adherence to clinic recommendations among patients with phenylketonuria in the United StatesMolecular Genetics and Metabolism, 2017
- Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With PhenylketonuriaDevelopmental Neuropsychology, 2016
- Phenylketonuria (PKU): A problem solved?Molecular Genetics and Metabolism Reports, 2016
- Phenylalanine hydroxylase deficiency: diagnosis and management guidelineGenetics in Medicine, 2014
- Correlation of age‐specific phenylalanine levels with intellectual outcome in patients with phenylketonuriaJournal of Inherited Metabolic Disease, 2011
- Psychiatric symptoms and disorders in phenylketonuriaMolecular Genetics and Metabolism, 2010
- Suboptimal outcomes in patients with PKU treated early with diet alone: Revisiting the evidenceMolecular Genetics and Metabolism, 2010
- Quality of life in noncompliant adults with phenylketonuria after resumption of the dietJournal of Inherited Metabolic Disease, 2008
- How practical are recommendations for dietary control in phenylketonuria?The Lancet, 2002